$Wave Life Sciences(WVE)$ As of December 31, 2022, Wave had $88.5 million in cash and cash equivalents, as compared to $150.6 million as of December 31, 2021. As previously disclosed, Wave entered into a strategic collaboration with GSK that became effective in the first quarter of 2023 and provided upfront cash of $170 million to Wave. Accordingly, the Company expects that its current cash and cash equivalents will be sufficient to fund operations into 2025. 合计现金2.55亿，后续主要靠gsk的里程碑收入；一年烧钱1.6亿；市值当前3.9亿